AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6131066 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 53
Study 30682835 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI diet
Number of subjects: 12
Study 30682835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 12
Study 29194205 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective eye shield (mask)
Number of subjects: 36
Study 29194205 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 36
Study 27155547 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Compression Fraction (CCF) during resuscitation
Number of subjects: 1997
Study 27155547 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Chest Compression Fraction (CCF)
Number of subjects: 1997
Study 24103444 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist geriatric medical management
Number of subjects: 433
Study 24103444 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 433
Study 22073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity peritoneal dialysis (prescribed Kt/V of 0.8 per session)
Number of subjects: 61
Study 22073842 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity peritoneal dialysis (prescribed Kt/V of 0.5 per session)
Number of subjects: 61
Study 22073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity peritoneal dialysis (prescribed Kt/V of 0.8)
Number of subjects: 61
Study 22073842 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity peritoneal dialysis (prescribed Kt/V of 0.5)
Number of subjects: 61
Study 22073842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 4 PD sessions
Number of subjects: 61
Study 19844115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (balanced hypocaloric diet, weekly meetings with dietician)
Number of subjects: 162
Study 19844115 — intervention group
Group type: COMPARATOR
Intervention: Exercise (90 min moderate exercise 3 days/week)
Number of subjects: 162
Study 19844115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise (balanced hypocaloric diet + 90 min moderate exercise 3 days/week)
Number of subjects: 162
Study 19844115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 162
Study 19844115 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 162
Study 19844115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 162
Study 17220958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy strategies
Number of subjects: 0
Study 17220958 — intervention group
Group type: COMPARATOR
Intervention: Advanced-phase studies
Number of subjects: 0
Study 15545857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax II
Number of subjects: 113
Study 15545857 — intervention group
Group type: COMPARATOR
Intervention: Mengivax A&C
Number of subjects: 113
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous combination of band ligation and sclerotherapy
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Metachronous approach using sclerotherapy after band ligation
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-occluded retrograde transvenous obliteration
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 0
Study 10718384 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound for Doppler studies
Number of subjects: 0
Study 9293051 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin suspension (7.5 mg/kg twice daily)
Number of subjects: 229
Study 9293051 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin syrup (125 mg/kg three times daily for body weight < 25 kg, or 250 mg/kg three times daily for body weight 25 kg)
Number of subjects: 229
Study 8112371 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 12
Study 8112371 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER 10 mg
Number of subjects: 12
Study 3571860 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric clinic care for 18 months
Number of subjects: 205
Study 3571860 — intervention group
Group type: COMPARATOR
Intervention: Traditional Veterans Administration care
Number of subjects: 205
Study 29199070 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine (Ar4)
Number of subjects: 72
Study 29199070 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine (Me2)
Number of subjects: 72
Study 27196663 — intervention group
Group type: EXPERIMENTAL
Intervention: Project AIM (Adult Identity Mentoring) intervention, details on dosage and duration not specified.
Number of subjects: 0
Study 27196663 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0
Study 24053794 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bipolar plasma vaporisation of the prostate (C‐BPVP)
Number of subjects: 180
Study 24053794 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bipolar vaporisation (S‐BPVP)
Number of subjects: 180
Study 24053794 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 180
Study 24053794 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐BPVP and S‐BPVP
Number of subjects: 180
Study 24053794 — intervention group
Group type: COMPARATOR
Intervention: C‐BPVP, S‐BPVP, and TURP
Number of subjects: 180
Study 22464673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with allergen tablets over a 4-month period
Number of subjects: 79
Study 22464673 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 79
Study 20973922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Number of subjects: 650
Study 20973922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study 18242584 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 16
Study 19153582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4376
Study 19153582 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4376
Study 15058795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon +/− 13‐cis‐retinoic acid
Number of subjects: 191
Study 12181464 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride (BC) vaginal suppository and bathing solution
Number of subjects: 107
Study 12181464 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository and bathing solution
Number of subjects: 107
Study 9542564 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air surface warming on upper extremities and upper thorax
Number of subjects: 24
Study 9542564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal heat exchanger
Number of subjects: 24
Study 9542564 — intervention group
Group type: COMPARATOR
Intervention: No active warming (control group)
Number of subjects: 24
Study 9542564 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of internal group (I and III) vs external group (II)
Number of subjects: 24
Study 8038233 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose Ara-C (200 mg/m2 d 1-5) combined with idarubicin (12 mg/m2 d 1-3)
Number of subjects: 23
Study 8038233 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose Ara-C/idarubicin
Number of subjects: 23
Study 3359906 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge elevation
Number of subjects: 15
Study 3359906 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation on blocks
Number of subjects: 15
Study 3359906 — intervention group
Group type: COMPARATOR
Intervention: Flat position
Number of subjects: 15
Study 11570630 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-I (IGF-I) levels measured in cerebrospinal fluid (CSF)
Number of subjects: 11
Study 11570630 — intervention group
Group type: COMPARATOR
Intervention: Control participants (11 participants; 6 females, 5 males; mean age 3.8 years)
Number of subjects: 11
Study 29529897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg/month for 6 months
Number of subjects: 13
Study 29529897 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Conv)
Number of subjects: 13
Study 30104008 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapies (LT)
Number of subjects: 0
Study 30104008 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy (MC)
Number of subjects: 0
Study 30650289 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaoyao Gancao Decoction (SGD)
Number of subjects: 120
Study 30650289 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine Tablet (OT)
Number of subjects: 120
Study 30650289 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SGD and OT)
Number of subjects: 120
Study 24940825 — intervention group
Group type: EXPERIMENTAL
Intervention: InsuPad (modulation device)
Number of subjects: 32
Study 24940825 — intervention group
Group type: COMPARATOR
Intervention: Control group (without device)
Number of subjects: 32
Study 24940825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 23141789 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (TFT)
Number of subjects: 45
Study 23141789 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 45
Study 19850944 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype of rs1042717 in patients with septic shock
Number of subjects: 1205
Study 18173143 — intervention group
Group type: EXPERIMENTAL
Intervention: Aike Decoction for smoothing Gan‐qi
Number of subjects: 218
Study 18173143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazhengsan Decoction for clearing heat and removing dampness
Number of subjects: 218
Study 18173143 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianliexianyan Decoction for promoting blood circulation to remove stasis
Number of subjects: 218
Study 18173143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group D)
Number of subjects: 218
Study 16274999 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/die)
Number of subjects: 40
Study 16274999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16274999 — intervention group
Group type: COMPARATOR
Intervention: Normal patients (control group)
Number of subjects: 40
Study 16274999 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary patients (baseline)
Number of subjects: 40
Study 12135285 — intervention group
Group type: EXPERIMENTAL
Intervention: WR279396
Number of subjects: 45
Study 12135285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9895383 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 42
Study 9895383 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation
Number of subjects: 42
Study 7845026 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (E. coli, 250 micrograms/m2/day, s.c.)
Number of subjects: 8
Study 7845026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7845026 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 8
Study 2220572 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/day)
Number of subjects: 1775
Study 2220572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1775
Study 883329 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after simple mastectomy
Number of subjects: 2268
Study 883329 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy in patients with positive nodes
Number of subjects: 2268
Study 883329 — intervention group
Group type: COMPARATOR
Intervention: Simple mastectomy followed by watch policy
Number of subjects: 2268
Study 30813212 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator (Group 3D)
Number of subjects: 52
Study 30813212 — intervention group
Group type: COMPARATOR
Intervention: Conventional simulator (Group C)
Number of subjects: 52
Study 28543041 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-PPV group (cardiac index and pulse pressure variation monitoring)
Number of subjects: 244
Study 28543041 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean arterial pressure-guided therapy only)
Number of subjects: 244
Study 28543041 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-PPV group
Number of subjects: 244
Study 28543041 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study 25657106 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (3 month programme)
Number of subjects: 1042
Study 25657106 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 1042
Study 25657106 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 1042
Study 24521775 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/pred
Number of subjects: 212
Study 24521775 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/CsA
Number of subjects: 212
Study 24521775 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/CsA/pred
Number of subjects: 212
Study 24521775 — intervention group
Group type: COMPARATOR
Intervention: CNI withdrawal
Number of subjects: 212
Study 24521775 — intervention group
Group type: COMPARATOR
Intervention: No rejection
Number of subjects: 212
Study 21907349 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus 0.5 L/min of room air via nasal prongs
Number of subjects: 87
Study 21907349 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 0.5 L/min with CO(2) (about 1% inhaled) by nasal prongs
Number of subjects: 87
Study 21907349 — intervention group
Group type: COMPARATOR
Intervention: CO(2) group
Number of subjects: 87
Study 19506333 — intervention group
Group type: EXPERIMENTAL
Intervention: pHGF treatment
Number of subjects: 49
Study 19506333 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 17443476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 534
Study 17443476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 17443476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis after trial closure
Number of subjects: 534
Study 17443476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups during ART availability
Number of subjects: 534
Study 15138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (50 mg daily)
Number of subjects: 0
Study 15138753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15167213 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in red meat intake
Number of subjects: 1905
Study 15167213 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of fish
Number of subjects: 1905
Study 12575393 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuhuang Shenmai injection (KHSM) combined with Astragalus decoction (AD)
Number of subjects: 186
Study 12575393 — intervention group
Group type: COMPARATOR
Intervention: Ribarvirin and ganlixin injection
Number of subjects: 186
Study 9627948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular methotrexate (MTX) therapy (10 mg injections every 3 to 7 days)
Number of subjects: 5
Study 9627948 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular triamcinolone hexacetonide (TC) therapy (40 mg single injection)
Number of subjects: 5
Study 8185271 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with lidocaine
Number of subjects: 40
Study 8185271 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 40
Study 2895909 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 250
Study 2895909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 2895909 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 250
Study 30274305 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinumtoxin A (IncoA)
Number of subjects: 24
Study 30274305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 24
Study 28012910 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank exercise (15 x 2 minutes bouts with 2 minutes rest)
Number of subjects: 11
Study 28012910 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm crank exercise
Number of subjects: 11
Study 28012910 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 26307566 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution (TrophAmine®)
Number of subjects: 430
Study 26307566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 430
Study 23223825 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 98
Study 23223825 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 98
Study 21620748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone
Number of subjects: 40
Study 17487227 — intervention group
Group type: EXPERIMENTAL
Intervention: CX516 900 mg three times daily
Number of subjects: 105
Study 17487227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16492602 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) injections
Number of subjects: 6
Study 16492602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride solution)
Number of subjects: 6
Study 16492602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 6
Study 12808541 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor 6-minute walk test (6MWT)
Number of subjects: 18
Study 12808541 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor 6-minute walk test (6MWT)
Number of subjects: 18
Study 11127459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g)
Number of subjects: 10
Study 11127459 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose loading (75 g) + vitamins C (2 g) and E (800 IU)
Number of subjects: 10
Study 8822657 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm tub bath during labor
Number of subjects: 1385
Study 8822657 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no bath)
Number of subjects: 1385
Study 1396832 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 11)
Number of subjects: 22
Study 1396832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 22
Study 3925290 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified niacin
Number of subjects: 71
Study 3925290 — intervention group
Group type: COMPARATOR
Intervention: Time-release niacin
Number of subjects: 71
Study 30724580 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured using anamnestic comparative self-assessment (range -5 to +5)
Number of subjects: 171
Study 31242671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Nordic Nutrition Recommendations (NNR)
Number of subjects: 5000
Study 31242671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetable intakes
Number of subjects: 5000
Study 31242671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake for women
Number of subjects: 5000
Study 30400111 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination retraining
Number of subjects: 80
Study 26919838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home patient
Number of subjects: 62
Study 26919838 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly trained patient actor
Number of subjects: 62
Study 26919838 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual patient
Number of subjects: 62
Study 26919838 — intervention group
Group type: COMPARATOR
Intervention: All groups (Nursing home, Elderly actor, Virtual)
Number of subjects: 62
Study 23180147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant group (FSG)
Number of subjects: 102
Study 23180147 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein group (LTG)
Number of subjects: 102
Study 22883307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinvasive approach (mechanical chest compression device, prehospital intraarrest cooling, extracorporeal life support, early invasive assessment)
Number of subjects: 0
Study 22883307 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 19250005 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Guided Imagery (IGI)
Number of subjects: 12
Study 19250005 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study 17768460 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion of 50‐250 ug.kg‐1.min‐1 after a bolus of 0.5 mgxkg‐1
Number of subjects: 40
Study 17768460 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.2‐0.5 ugxkg‐1xmin‐1
Number of subjects: 40
Study 17768460 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Esmolol and Remifentanil)
Number of subjects: 40
Study 17768460 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study 16163242 — intervention group
Group type: EXPERIMENTAL
Intervention: New cytotoxic agents and novel targeted therapies
Number of subjects: 0
Study 16163242 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 16163242 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapeutics
Number of subjects: 0
Study 12439769 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Sal, 6 mg)
Number of subjects: 8